BioMarin delays refiling approval request for hemophilia gene therapy
The once-and-done gene therapy, initially rejected by the FDA in summer 2020, could potentially provide a genetic fix for a bleeding disorder that today can require multiple prophylactic injections a week.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Ron Leuty Source Type: news